Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,165.08
(
0.80%
)
US TECH 100
26,524.40
(
-0.12%
)
Dow Jones
49,247.66
(
-0.13%
)
Brent Oil
102.33
(
0.78%
)
Bitcoin
77,649.89
(
-1.28%
)
News Focus
News Focus
Post# of 438
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DanWebzster

Send PM Follow Ignore
Followers 10
Posts 1063
Boards Moderated 2
Alias Born 09/04/2000

DanWebzster

Member Level

Re: DanWebzster post# 252

Wednesday, 07/18/2018 10:15:57 AM

Wednesday, July 18, 2018 10:15:57 AM

Post# of 438
FENC is a biotech with one valuable product and dwindling cash

Pedmark is a Breakthrough Therapy that protects pediatric cancer patients against Cisplatin-induced hearing loss.

FENC anticipates filing an NDA for Pedmark H2/18.

The best outcome for shareholders would be a buy out. FENC does not have the capital necessary to market the drug.

Some believe that FENC could fetch $12-15/share without further dilution.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Where Real Traders Talk Markets

Join thousands of traders sharing insights, catalysts, and charts.

Join Today